Brief: OliX Pharmaceuticals Announces FDA Clearance Of The IND To Evaluate The Efficacy Of OLX10010 In Phase 2A Clinical Trial For Hypertrophic Scars
30/10/2020 15:52
Oct 30 (Reuters) - OliX Pharmaceuticals Inc 226950.KQ :
* OLIX PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF THE IND TO
EVALUATE THE EFFICACY OF OLX10010 IN PHASE 2A CLINICAL TRIAL FOR
HYPERTROPHIC SCARS
* OLIX PHARMACEUTICALS INC - RETAINS GLOBAL RIGHTS TO
DEVELOP AND
COMMERCIALIZE OLX10010 OUTSIDE ASIA
Source text for Eikon: urn:newsml:reuters.com:*:nGNX8xcfVQ
Further company coverage: 226950.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment